On February 15, 2020, Sirim, Mustafa Mert; Krishna, Vagolu Siva; Sriram, Dharmarajan; Unsal Tan, Oya published an article.Product Details of 890092-19-0 The title of the article was Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity. And the article contained the following:
The synthesis and evaluation of some benzimidazole-acrylonitrile hybrid derivatives I [R = Me, cyclohexyl, benzyl, etc.] was described for their in-vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv. Among the derivatives studied, I [R = p-tolyl] was found to be the most active compound with MIC of 0.78μg/mL against M. tuberculosis. This was a quite good activity compared with ethambutol (MIC = 1.56μg/mL). Moreover, I [R = p-tolyl] showed 2.8 log fold reduction in bacterial count of dormant forms of mycobacterium which was more potent than first line drugs isoniazid, ciprofloxacin, rifampicin and moxifloxacin. Having activities against both active and dormant forms of M. tuberculosis, I [R = p-tolyl] may be a useful candidate for the development of new drugs to treat tuberculosis. The experimental process involved the reaction of 4-(4-Acetylpiperazin-1-yl)benzaldehyde(cas: 890092-19-0).Product Details of 890092-19-0
The Article related to benzoimidazolyl phenylpiperazinyl acrylonitrile preparation antimycobacterial activity sar lipophilicity, propanenitrile benzoimidazolyl phenylpiperazinyl preparation antimycobacterial activity sar lipophilicity, acrylonitrile, antimycobacterial activity, benzimidazole, nutrient starvation test, propanenitrile and other aspects.Product Details of 890092-19-0
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics